Retrospective analysis of clinical trial safety data for pembrolizumab reveals the effect of co-occurring infections on immune-related adverse events

Biologics targeting PD-1, PD-L1, and CTLA-4 immune checkpoint proteins have been used in a variety of tumor types including small and non-small cell lung cancers, melanoma, and renal cell carcinoma. Their anti-tumor activity is achieved through amplifying components of the patient’s own immune syste...

Descripción completa

Detalles Bibliográficos
Autores principales: Makunts, Tigran, Burkhart, Keith, Abagyan, Ruben, Lee, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830697/
https://www.ncbi.nlm.nih.gov/pubmed/35143542
http://dx.doi.org/10.1371/journal.pone.0263402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830697/
https://www.ncbi.nlm.nih.gov/pubmed/35143542
http://dx.doi.org/10.1371/journal.pone.0263402

Ejemplares similares